Brain/MINDS (Brain Mapping by Integrated Neurotechnologies for Disease Studies) is a national brain project started by Japan in 2014. With the goal of developing the common marmoset as a model animal for neuroscience, the project aims to build a multiscale marmoset brain map, develop new technologies for experimentalists, create transgenic lines for brain disease modeling, and integrate translational findings from the clinical biomarker landscape. Brain/MINDS will collaborate with global brain projects to share technologies and resources.
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Brain/MINDS: A Japanese National Brain Project In 2013, following a remarkable convergence of scientific advocacy and political vision, two large-scale national research projects, the U.S. BRAIN Initiative and the EU Human Brain Project (HBP), were launched to accelerate the scientific understanding of the brain. In Japan, this movement mobilized the neuroscience community to consider how to contribute to global affairs in neuroscience. Policy discussions identified brain research in non-human primates as a necessary step to bridge fundamental advances from current animal models, such as the mouse, to an accurate understanding of the human brain. For disease studies, in particular, scientific knowledge from the primate brain was seen as an indispensable component of translational research toward evidence-based diagnosis and treatment of human psychiatric, neurological, and neurodegenerative disorders. The conclusion of this discussion called for Japan to adopt a fundamentally different approach compared to the larger scale and broader scope of the U.S. and EU brain projects, by focusing on accelerating the development of the common marmoset (Callithrix jacchus), a small new world primate, as a model for exploration and discovery of knowledge-based strategies for the eradication of major brain disorders (Grillner et al., 2016; Okano et al., 2015; Okano and Yamamori, 2016) . Based on these considerations, the Brain/MINDS (Brain Mapping by Integrated Neurotechnologies for Disease Studies) initiative was launched in June 2014 with support from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT) and the newly formed Japan Agency for Medical Research and Development (AMED) (see Box 1 in detail). The 10 year roadmap for Brain/MINDS mandates completion of a multiscale marmoset brain atlas and integrated data platform to support functional studies, the generation of genetically modified (GM) marmosets for experimental and pre-clinical studies, and the creation of a clinical data center using translational biomarkers for the diagnosis and treatment of human brain diseases (Figure 1 ).
Brain/MINDS is comprised of 65 laboratories at 47 institutions in Japan and several partner countries. The research organization involves four major groups (http://www.brainminds.jp/): (A) Structural and functional mapping of the marmoset brain, (B) Development of innovative neurotechnologies for brain mapping, (C) Human brain mapping and clinical research, and (D) Advanced technology and application development. This structure is designed for each group to serve as a virtual research hub for collaboration both within the project and with external partners. Group A is constructing an integrated structural map of the marmoset brain at the macro-, meso-, and microspatial scales, as a foundational template for overlaying functional mapping data derived chiefly from brain imaging technologies including fMRI, PET imaging, calcium imaging, and in situ gene expression. The additional aims of Group A include the development of marmoset behavioral assays and analytical systems and the generation of genetically modified marmoset disease models. Group B is involved in the development of innovative technologies for marmoset brain mapping at the Brain/MINDS project core research institutes, including tissue clearing, labeling, and microscopy techniques, and the generation of integrated marmoset databases. Group D, composed of laboratories throughout Japan, will help to expand the toolbox of affiliated technologies for brain mapping and functional studies in conjunction with Group B. Group C will use human functional imaging to map large cohorts of normal and patient brain. This group, composed of three clinical research teams for neuropsychiatric disorders, cerebrovascular disease, and neurodegenerative disease, will build a multi-center database of patient-derived imaging and other translatable biomarkers for clinical diagnosis and treatment and reverse application to ongoing marmoset studies of disease mechanisms and pre-clinical studies (Grillner et al., 2016; Okano et al., 2015) . Collectively, Groups A-D will establish common platforms and programs for sharing experimental resources, technologies, and data to accelerate domestic and international marmoset brain research.
A Marmoset Experimental Model for Neuroscience
The common marmoset maintains a unique phylogenetic position as an experimental model animal for neuroscience. Certain higher cognitive behaviors, and their affiliated brain diseases, may in some cases be easier or more accurate to study in a non-human primate than in rodent or other simple vertebrate models. Underlying these cognitive behaviors, the human brain is composed of structures conserved throughout the mammalian lineage but also those unique to humans and non-human primates. The cognate brain structures that contain these emergent brain functions are evolutionarily recent and typically acquired through enlargement of the cerebral neocortex (Izpisua Belmonte et al., 2015) . For example, the primate prefrontal cortex responsible for cognitive processes like prefrontal-based working memory, and the expression of some psychiatric disorders, has no clear homolog in rodents (Wise, 2008) , suggesting advantages of non-human primate models for modeling Grillner et al. (2016) , Okano et al. (2015) , and Okano and Yamamori (2016) Genetically modified (GM) marmosets are being produced by viral vector and genome editing techniques. Rapid breeding methods for GM and cloned marmosets are ongoing in the SRBPS project. In the Brain/MINDS project, multimodal imaging is being developed along with analytical and bioinformatics tools. The data in this figure were kindly provided by Drs. Jun-ichi Hata, Fumiko Seki, Shinsuke Shibata, and Akiya Watakabe. the human brain and mental illness. These behaviors, often distinct and/or more sophisticated than in rodent and other primate models, are linked to advanced development of the frontal lobe and connected subcortical brain areas indicative of complex neural circuitries. However, given the limitations in non-invasive and invasive methodologies for understanding the human brain, it is essential to examine cognate behaviors in non-human primates and develop in vivo biomedical models for human neurological, psychiatric, and neurodegenerative diseases in non-human primates. The macaque is a well-established primate model that will continue to make central contributions to neuroscience but due to animal handling, husbandry, and other practical issues, other non-human primate models like marmoset may serve in complementary scientific roles.
Given these considerations, the marmoset will be useful as a non-human primate model to understand the brain mechanisms of discrete higher cognitive behaviors and as a bridge from the rodent to clinical studies. Furthermore, various research tools and resources including genome sequence information (Sato et al., 2015) , anatomical and MRI atlases (Hikishima et al., 2013) , and genome modifying technologies (Sasaki et al., 2009; Sato et al., 2016) have been developed for marmoset. Importantly, this technological foundation makes the marmoset a potentially useful species for neurological disease models, such as stroke, Parkinson's disease, spinal cord injury, and multiple sclerosis that are currently available, and new models for psychiatric, neurodevelopmental, and neurodegenerative diseases that are in the pipeline. Drug metabolism and pharmacokinetics/pharmacodynamics in marmoset, essential for conducting preclinical studies, are in development, including projects on the genetic heterogeneity of P450 enzymes (Uno et al., 2016) . Considering these advantages in the context of genetically modifying technologies described below, the marmoset has the potential to be a useful model in neuroscience. Further development of the research infrastructure for this model including economies of scale, community building, open data, and clinical and drug development strategy will be essential to expand this limited scientific model to wider adoption.
Pioneering Genetic Modification Technologies
One of the essential factors that policymakers considered in planning Brain/ MINDS is whether there was a unique and historical foundation for marmoset research in Japan. Notably, Japan has a long history of research in marmoset breeding and reproduction studies. Tatsuji Nomura, the founder of the Central Institute of Experimental Animals (CIEA), started in-house marmoset colonies, considering their potential in applications for biomedical science, as early as 1975. This long-standing expertise and knowledge on marmoset breeding in Japan resulted in the accelerated development of transgenic marmoset technologies. Initially, several methods at transgenesis were attempted, including linear DNA injection into fertilized eggs and injection of marmoset ES cells carrying transgenes into the blastocyst. Ultimately, the injection of a non-replicating lentiviral vector carrying a foreign gene encoding EGFP reliably produced transgenic marmosets (Sasaki et al., 2009) , representing the first successful generation of transgenic nonhuman primates with germline transmission. This technology has been used for the generation of various neurological disease-model marmosets, including those for Parkinson's disease, Alzheimer disease's, and ALS (amyotrophic lateral sclerosis) using gain of toxic function via transgenes that encode aggregationprone mutant proteins (Grillner et al., 2016) . However, in the longer term, lentiviral vector-mediated gene transfer has clear limitations and new technologies for gene modification of common marmosets are being developed in the project, in addition to lenti-viral-mediated gene transfer (Sasaki et al., 2009 ). Lines of targeted gene knockout (KO) marmosets have been generated using genome editing technologies (Sato et al., 2016) , which could also have a large impact on researchers in neuroscience and other life science fields toward the development of non-human primate disease models. Looking to the future, more efficient and innovative GM technologies in marmoset using genome editing will be required for the generation of cell-type-specific marmoset Cre lines through knockin strategies (Table 1) . Currently, the generation of knockout marmosets is possible. On the other hand, it is also important to develop new technologies for generating GM marmosets, other than lentiviralmediated gene transfer and genome editing. A current hurdle is that germlinecompetent marmoset ESCs are not available. The genomes of ESCs can be intensively and effectively modified, and development of naive germline-competent marmoset ESCs for next-generation GM marmosets is in progress. Recently, there have also been efforts to generate genetically identical marmosets by cloning techniques using nuclear transfer for the availability of genetically definable GM marmosets. Using these methods, the generation and characterization of additional GM marmoset lines for modeling human neurological and psychiatric disorders including Alzheimer disease's, autism, and schizophrenia will be pursued (Table 1) . Abnormalities in brain structure and function in these marmoset models may accelerate discovery of disease biomarkers and mechanisms toward translation.
Integrative Multiscale Marmoset Brain Mapping
One of the chief goals of Brain/MINDS is to generate a comprehensive multiscale anatomical map of the marmoset brain. The map will be used to register and interpret functional mapping studies, as a control atlas for detailed comparisons to marmoset disease models for biomarker discovery, as a workspace for integrating human cognition and disease biomarkers to drive reverse translational studies, and as a resource for the global marmoset research community. At the macroscopic level, Brain/MINDS is using a high-field 9.4 T MRI scanner for high-resolution structural imaging of the marmoset brain at a 60 3 60 3 60 mm 3 voxel size. Marmosets will be comprehensively scanned in various configurations (e.g., T1WI, T2WI, DTI, myelin map) to establish a quantitative database with the resolution to measure variability in anatomical structures across individual animals. The scanner will also be used for concurrent functional brain mapping studies involving restingstate and task-based fMRI in awake marmosets to investigate the extent to which the marmoset brain shares functional architecture with the human brain. Another important study using MRIbased macroscale mapping is the developing marmoset brain. In addition to a developmental atlas during the embryonic and fetal stages, an age-specific multi-contrast atlas will serve as a framework for prenatal and postnatal brain development research. Structural MRI studies such as careful delineation of growth patterns in region-specific manner as ''ontogenic parcellation maps,'' and expanding how it links to developmental pattern of brain functions, are both important tasks for a deeper understanding of typical growth and aging patterns and investigation of various diseases model marmosets (e.g., autism, schizophrenia, dementia, and others) affecting different stages ranging from fetus to aged stages. Such frameworks will be able to discriminate atypical neurodevelopmental disease models and be able to improve understanding of how development in marmosets compares to that in humans.
In parallel with the above effort to construct MRI-based macroscopic brain mapping in the marmoset, multiple Brain/MINDS teams in Japan and several partner countries are working together to construct a neuronal connectivity map of marmoset brain at the mesoscopic level. Injection of AAVs containing a GFP expression vector will interrogate the connections to and from frontal, dorsal, and temporal neocortex using standardized procedures and vector constructs and ex vivo MRI imaging following virus injections. The groups will construct a mesoscopic connection matrix comparable with that formed by MRI mapping. Concurrently, neuroanatomical tracers will be introduced in cortical areas to map connections in the same animals scanned by MRI to allow bidirectional convergence of macroscopic anatomical information obtained by MRI and mesoscale neuroanatomical information obtained by neurohistological techniques. Comparison of the connective maps obtained by different methods will allow comparisons across both anatomical scale and in comparative analysis of human and non-human primate brain. Expanding the multiscale map integration to additional scales, scanning electron microscope (SEM) and micro-connectome analyses will allow construction of a three-dimensional (3D) neural circuit maps of neocortex and correlative analysis, and linkage of results from fluorescence and electron microscopy. In the clinical domain, MRI brain images in human will be integrated with the marmoset atlas with neural mechanisms studied in animal experiments. The Brain/MINDS projects aims at integrating not only different levels of structural mapping information obtained by MRI, tracer injection, and SEM, but also different types of information based on functional mapping, disease models, behavioral studies, and molecular/cellular data. A wealth of information from mice on brain function and structure is now being rapidly accumulated, and Brain/MINDS complementary focus on the marmoset brain will serve as a bridge to integrate structural, behavioral, and physiological information across model species and apply this information to humans for mechanistic and disease studies.
Molecular Cartography and Tool Development
A cornerstone of Brain/MINDS is connecting anatomical maps, functional neural circuit studies, and molecular disease mechanisms. To achieve this mission, brain-wide genomic and protein distribution mapping and their affiliated technologies will be conducted. Brain/MINDS is developing an in situ hybridization (ISH)-based gene expression database of the common marmoset brain (Mashiko et al., 2012) , aiming to provide information and develop knowledge-based tools to explore primate-specific brain structure, function, and connectivity in healthy and disease conditions. In particular, the analysis of gene expression patterns for identified autism risk genes in neonatal marmoset brain will be analyzed for cell-type-and layer-specific expression, and restricted sub-layer patterning, and compared to the same genes' expression patterns in mouse brain. This comparative approach between marmoset and mouse reflects the idea that if the marmoset is to be used as a productive genetic model for bridging rodent and primate neurobiology, analyzing the relationship of brain genomic development between the two species is critical. Therefore, Brain/ MINDS will establish a web-accessible, genome-wide, high-resolution atlas to systematically analyze changes in gene expression over the course of postnatal brain development to the adult stage (https://gene-atlas.bminds.brain. riken.jp/) (Figure 2 (Saito et al., 2014) , 3D spatial networks of amyloid-b plaques, neurons, and microglia were visualized (Hama et al., 2015) . Furthermore, ScaleS clearing enabled successive light and electron microscopy to zoom in on single amyloid plaques at diverse spatial scales in AD mouse models and AD human brains.
In addition to anatomical mapping, comprehensive behavioral and physiological analyses are critical for accurate assessment of functional behavior. Brain/MINDS is undertaking the development of a systematic test battery for marmoset cognitive and social behaviors comprised of a suite of touch-panelbased cognitive tasks, motion tracking, and Wi-Fi neural recording systems, wearable devices for physiological monitoring, and algorithms for their integrated analyses (Patents pending, #Japan, #USA, #EU, #Singapore). This system will be used for the analysis of natural marmoset behaviors, comparative neurobiology, and validation of disease model marmosets. To deliver additional technologies for physiological studies in awake behaving marmosets, the Brain/MINDS technology development Groups B and D are building an array of marmoset-compatible recording devices including multichannel silicon probes, two-photon imaging with GCaMP-based calcium GECIs, and ECoG arrays in head-fixed and freely moving configurations. These technologies used in conjunction with GM marmosets and multiscale brain mapping data will allow detailed analyses of neural circuit mechanisms
Computational Platforms for Data Integration
Given the diversity of data generated by Brain/MINDS neuroinformatics tools will be required to integrate different levels of information drawn from methodologies used at various scales. MRI, DTI, tracer injections, and SEM provide information at levels up to the 10 9th order (from 1 mm to 1 nm). MRI and DTI informatics technologies at a macroscopic level are well advanced and standardized (e.g., http:// www.fil.ion.ucl.ac.uk/spm/software/). In contrast, at the mesoscopic and microscopic connectome level (e.g., Oh et al., 2014; Morgan et al., 2016) , standard methods are not yet established in any mammal. Despite the difficulties in integrating multiscale mapping data across species, these approaches could proceed in parallel with the effort of constructing intraspecies mesoscopic and macroscopic maps because they would help to mutually refine the connectivity maps with each other. Brain/MINDS will construct a comparative brain map of marmosets, macaques and humans based on the databases and anticipated development of new data analysis and viewer methods. Importantly, Brain/ MINDS scientific databases will be open source with priority given to researchers and managed by a database committee to oversee data collection and use. The Neuroinformatics Japan Center based at RIKEN BSI is constructing the web database for data sharing and research collaboration, including the Brain/MINDS research platform database and Brain/MINDS publication platform database (https://www.bminds.brain. riken.jp/). Research data generated by individual laboratories are curated and stored as pairs of metadata and datasets in the research platform database. The data analysis environment consisting of data formatting and data analysis pipelines is capable of large-scale shared storage, with support from HPCs and VDI cloud servers linked over high-velocity networks. The publication platform database will be constructed for public use of the Brain/MINDS database and its linkage with external databases. These facilities and related activities will cover the majority of the data in the project aimed at integration of the structural and functional marmoset brain maps. The publication platform will open in 2017. Subsequent efforts will focus on the integration of structural, behavioral and functional aspects using marmoset models. A combined Nissl stain and MRI-based freely rotatable volume-rendered 3D digital brain atlas (Hashikawa et al., 2015) will provide the fundamental template for the common marmoset brain database with registration of data from the entire project. Architectural information from this atlas will be useful for aligning MRI studies from participating labs. This atlas is now shared with the Neuroinformatics Platform of the European Human Brain Project's search engine for brain atlases (https://nip.humanbrainproject.eu) and will serve as an international platform for distributed data, curated data repositories, and brain knowledge.
Promoting Evidence-Based Clinical Brain Research
In Brain/MINDS, marmoset brain research is not viewed as an end in itself, but only a means to eventual better diagnoses and treatments of human brain disorders. To begin the process of saving lives, Brain/MINDS initiated a clinical research group to address human brain disorders and collect the type of integrative evidence that could eventually connect bidirectionally to information collected from marmoset disease models. The missions of the clinical research Group C include (1) the identification of disease-related neural circuit endophenotypes using neuroimaging, neurophysiological, and behavioral data, (2) the discovery and development of psychiatry-oriented brain translatable biomarkers that can be measured by techniques common to humans and primates, and (3) the establishment of neural circuit markers useful for re-classification strategies for psychiatric disorders and the development of innovative treatments for these diseases (reviewed in Okano et al., 2015; Grillner et al., 2016; Okano and Yamamori, 2016) . In a recent example of this approach, a large-scale multisite study of subcortical volumetric differences was conducted on a large cohort of schizophrenia patients (Okada et al., 2016) . T1-weighted images obtained using 15 imaging protocols at 11 sites were processed with FreeSurfer. Schizophrenia patients had a smaller volume in hippocampus, amygdala, thalamus, and nucleus accumbens, but a larger bilateral caudate, putamen, and pallidum, replicating the rank order of effect sizes for subcortical volumetric changes in schizophrenia reported by the ENIGMA consortium. A schizophrenia-specific leftward asymmetry in pallidum volume suggests the possibility of aberrant laterality in neural pathways and connectivity patterns. Other candidates for translatable brain markers include neurophysiological indices such as mismatch negativity (MMN) (Nagai et al., 2013) and auditory steady-state gamma-band oscillatory responses (ASSRs), indices that could be applied to both human and non-human primates. Given existing biomarkers for glutamatergic and GABAergic neurotransmission in schizophrenia, the development of an electrocorticogram (ECoG) measurement protocol applicable to primates may allow a breakthrough toward understanding disease-related circuit abnormalities and optimizing drug discovery, which have been great challenges in psychiatry. Major limitations in current psychiatric research include a lack of evidence linking microscopic-level abnormalities in rodent models (e.g., synaptic dysfunction), macroscopic-level neuroanatomical (e.g., gray matter volume) and neurophysiological (e.g., MMN, ASSR) abnormalities, and consequent behavioral changes in patients. Applying combinations of macroscopic translatable brain biomarkers, mesoscopic circuit manipulation technologies, and microscopiclevel imaging to marmoset disease models from the Brain/MINDS project will identify cause-effect links among multi-level abnormalities, a necessary step toward etiology-based drug discovery and a rational neurocircuit-based reclassification of psychiatric disorders.
Supporting Global Progress in Brain Research
From the launch of Brain/MINDS in 2014, the marmoset neuroscience research field has had access to the project's data, resources, and equipment. However, the goal of Brain/MINDS scientific program is expected to expand to wider international collaboration. To contribute to global progress in brain research, Brain/MINDS will actively participate in worldwide brain mapping projects and their coordination and is prepared to transfer marmoset technologies, GM lines, and research data to the global research community. In addition, the China Brain Project will focus on GM technologies of macaque monkeys. Thus synergistic cooperation between China and Brain/MINDS would contribute to the efficient development of new technologies for GM non-human primates and psychiatric/neurological disease models. Likewise, the collaboration of Brain/ MINDS with the BRAIN Initiative, Human Brain Project, and other national efforts would be mutually beneficial. The coordination of international brain projects is discussed in other recent reviews (Grillner et al., 2016; Okano and Yamamori, 2016) . 
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